Development of novel signal transduction inhibitors; recent phase I trials

Affiliations

Comment

Ronald M Bukowski. Curr Oncol Rep. 2002 Jan.

. 2002 Jan;4(1):7-8.

doi: 10.1007/s11912-002-0042-y.

¹ Experimental Therapeutics Program, Cleveland Clinic Cancer Center, S33, 9500 Euclid Avenue, Cleveland, OH 441195, USA.

No abstract available

Comment on

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silberman S, Rowinsky EK. Hidalgo M, et al. J Clin Oncol. 2001 Jul 1;19(13):3267-79. doi: 10.1200/JCO.2001.19.13.3267. J Clin Oncol. 2001. PMID: 11432895 Clinical Trial.